1-2 of 2
Marja Mergui-Roelvink
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir

Vincent A. de Weger, Frederik E. Stuurman, Stijn L.W. Koolen, Johannes J. Moes, Jeroen J.M.A. Hendrikx, Emilia Sawicki, Bas Thijssen, Marianne Keessen, Hilde Rosing, Marja Mergui-Roelvink, Alwin D.R. Huitema, Bastiaan Nuijen, Jos H. Beijnen, Jan H.M. Schellens, Serena Marchetti
Journal: Clinical Cancer Research
Clin Cancer Res (2019) 25 (18): 5466–5474.
https://doi.org/10.1158/1078-0432.CCR-17-2299
Published: 13 September 2019
View article titled, A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir
Open the PDF for A Phase I Dose Escalation Study of Once-Weekly Oral Administration of Docetaxel as ModraDoc001 Capsule or ModraDoc006 Tablet in Combination with Ritonavir in another window
Journal Articles

Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors

Marlies H.G. Langenberg, Petronella O. Witteveen, Jeanine M. Roodhart, Henk M.W. Verheul, Marja Mergui-Roelvink, Jana van der Sar, Erich Brendel, Nicole Laferriere, Jan H.M. Schellens, Emile E. Voest
Journal: Clinical Cancer Research
Clin Cancer Res (2010) 16 (7): 2187–2197.
https://doi.org/10.1158/1078-0432.CCR-09-2436
Published: 31 March 2010
View article titled, Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors
Open the PDF for Phase I Evaluation of Telatinib, a Vascular Endothelial Growth Factor Receptor Tyrosine Kinase Inhibitor, in Combination with Irinotecan and Capecitabine in Patients with Advanced Solid Tumors in another window